RETINOIC ACID RECEPTOR-ALPHA
Homo sapiens
State in the Current Structure
| Assembly | Oligomeric State | Construct | Mutations and Modifications | Ligands, Ions and Associated Components | Method and Experimental Conditions | Structure Quality |
|---|---|---|---|---|---|---|
| 1 | Protein monomer Monomer Protein × 1 PDB declaration: monomeric（1） Consistent with protein copy count | Chain A； UniProt 130–212 | Fragment：DNA-BINDING DOMAIN, 130-212 Mutation：C195A | ZN ZINC ION × 2 | SOLUTION NMR NMR measurement conditions：pH 6.6；300 K；Ionic strength (raw mmCIF value) 120；Pressure AMBIENT NMR sample composition：WATER | Resolution not provided |
Other States of the Same Protein in the Database
Each row is a biological assembly of the same UniProt protein in another PDB entry. The “Difference from current entry” column identifies evidence-level differences; no tag means the currently parsed fields agree.
| Other PDB | Difference from Current Entry 1RXR | Assembly / Oligomeric State | Construct | Mutations and Modifications | Ligands, Ions and Non-polymers | Method and Experimental Conditions | Structure Quality |
|---|---|---|---|---|---|---|---|
| 1BY4 STRUCTURE AND MECHANISM OF THE HOMODIMERIC ASSEMBLY OF THE RXR ON DNA Deposited 1998-10-22 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein–DNA Homooligomer；Protein × 2 PDB declaration: tetrameric |
Chain A
128–209（82 aa）
Chain B
128–209（82 aa）
|
Not recorded | ZN ZINC ION × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7.5；25 MM TRIS BUFFER (PH 7.5),20% PEG3350, 5 MM MGCL2, 400MM NH4CL
|
Resolution 2.10 Å R-free 0.284 |
| 1BY4 STRUCTURE AND MECHANISM OF THE HOMODIMERIC ASSEMBLY OF THE RXR ON DNA Deposited 1998-10-22 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein–DNA Homooligomer；Protein × 2 PDB declaration: tetrameric |
Chain C
128–209（82 aa）
Chain D
128–209（82 aa）
|
Not recorded | ZN ZINC ION × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7.5；25 MM TRIS BUFFER (PH 7.5),20% PEG3350, 5 MM MGCL2, 400MM NH4CL
|
Resolution 2.10 Å R-free 0.284 |
| 1DSZ STRUCTURE OF THE RXR/RAR DNA-BINDING DOMAIN HETERODIMER IN COMPLEX WITH THE RETINOIC ACID RESPONSE ELEMENT DR1 Deposited 2000-01-10 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein–DNA Heteromer；Protein × 2 PDB declaration: tetrameric |
Chain B
129–212（84 aa）
Fragment：RESIDUES 129-212
|
Not recorded | ZN ZINC ION × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；281 K；18-23% PEG 3350, 25 mM Tris buffer, 5 mM MgCl2, 0.4 M NH4CL,
RXR and RAR proteins each at 0.45 mM, DNA duplex at 0.45 mM, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 281K
|
Resolution 1.70 Å R-free 0.267 |
| 1FBY CRYSTAL STRUCTURE OF THE HUMAN RXR ALPHA LIGAND BINDING DOMAIN BOUND TO 9-CIS RETINOIC ACID Deposited 2000-07-17 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
224–462（239 aa）
Fragment：LIGAND BINDING DOMAIN
Chain B
224–462（239 aa）
Fragment：LIGAND BINDING DOMAIN
|
Not recorded | 9CR (9cis)-retinoic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOUR DIFFUSION, HANGING DROP and SITTING DROP with SEEDING；pH 7；295 K；Sodium Formate,
Propane 1,2 Diol,
Glycerol,
Tris, pH 7, VAPOUR DIFFUSION, HANGING DROP and SITTING DROP with SEEDING, temperature 295K
|
Resolution 2.25 Å R-free 0.263 |
| 1FM6 THE 2.1 ANGSTROM RESOLUTION CRYSTAL STRUCTURE OF THE HETERODIMER OF THE HUMAN RXRALPHA AND PPARGAMMA LIGAND BINDING DOMAINS RESPECTIVELY BOUND WITH 9-CIS RETINOIC ACID AND ROSIGLITAZONE AND CO-ACTIVATOR PEPTIDES. Deposited 2000-08-16 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain A
225–462（238 aa）
Fragment：LIGAND BINDING DOMAIN - RESIDUES 225 -462
|
Not recorded | 9CR (9cis)-retinoic acid × 1 BRL 2,4-THIAZOLIDIINEDIONE, 5-[[4-[2-(METHYL-2-PYRIDINYLAMINO)ETHOXY]PHENYL]METHYL]-(9CL) × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；295 K；17% PEG 4K, 200mM NaSCN, 8% Ethylene Glycol, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 295K
|
Resolution 2.10 Å R-free 0.292 |
| 1FM6 THE 2.1 ANGSTROM RESOLUTION CRYSTAL STRUCTURE OF THE HETERODIMER OF THE HUMAN RXRALPHA AND PPARGAMMA LIGAND BINDING DOMAINS RESPECTIVELY BOUND WITH 9-CIS RETINOIC ACID AND ROSIGLITAZONE AND CO-ACTIVATOR PEPTIDES. Deposited 2000-08-16 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain U
225–462（238 aa）
Fragment：LIGAND BINDING DOMAIN - RESIDUES 225 -462
|
Not recorded | 9CR (9cis)-retinoic acid × 1 BRL 2,4-THIAZOLIDIINEDIONE, 5-[[4-[2-(METHYL-2-PYRIDINYLAMINO)ETHOXY]PHENYL]METHYL]-(9CL) × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；295 K；17% PEG 4K, 200mM NaSCN, 8% Ethylene Glycol, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 295K
|
Resolution 2.10 Å R-free 0.292 |
| 1FM9 THE 2.1 ANGSTROM RESOLUTION CRYSTAL STRUCTURE OF THE HETERODIMER OF THE HUMAN RXRALPHA AND PPARGAMMA LIGAND BINDING DOMAINS RESPECTIVELY BOUND WITH 9-CIS RETINOIC ACID AND GI262570 AND CO-ACTIVATOR PEPTIDES. Deposited 2000-08-16 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain A
225–462（238 aa）
Fragment：LIGAND BINDING DOMAIN - RESIDUES 225 - 462
|
Not recorded | 9CR (9cis)-retinoic acid × 1 570 2-(2-BENZOYL-PHENYLAMINO)-3-{4-[2-(5-METHYL-2-PHENYL-OXAZOL-4-YL)-ETHOXY]-PHENYL}-PROPIONIC ACID × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；295 K；17% PEG 4K, 200mM NaSCN, 8% Ethylene Glycol , pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 22K
|
Resolution 2.10 Å R-free 0.268 |
| 1G1U THE 2.5 ANGSTROM RESOLUTION CRYSTAL STRUCTURE OF THE RXRALPHA LIGAND BINDING DOMAIN IN TETRAMER IN THE ABSENCE OF LIGAND Deposited 2000-10-13 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
225–462（238 aa）
Fragment：LIGAND BINDING DOMAIN (RESIDUES 225 - 462)
Chain B
225–462（238 aa）
Fragment：LIGAND BINDING DOMAIN (RESIDUES 225 - 462)
Chain C
225–462（238 aa）
Fragment：LIGAND BINDING DOMAIN (RESIDUES 225 - 462)
Chain D
225–462（238 aa）
Fragment：LIGAND BINDING DOMAIN (RESIDUES 225 - 462)
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；295 K；20mM HEPES pH 7.5,
1.5M LiSO4,
10mM DTT
, VAPOR DIFFUSION, HANGING DROP, temperature 295K
|
Resolution 2.50 Å R-free 0.271 |
| 1G5Y THE 2.0 ANGSTROM RESOLUTION CRYSTAL STRUCTURE OF THE RXRALPHA LIGAND BINDING DOMAIN TETRAMER IN THE PRESENCE OF A NON-ACTIVATING RETINOIC ACID ISOMER. Deposited 2000-11-02 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
225–462（238 aa）
Fragment：LIGAND BINDING DOMAIN (RESIDUES 225 - 462)
Chain B
225–462（238 aa）
Fragment：LIGAND BINDING DOMAIN (RESIDUES 225 - 462)
Chain C
225–462（238 aa）
Fragment：LIGAND BINDING DOMAIN (RESIDUES 225 - 462)
Chain D
225–462（238 aa）
Fragment：LIGAND BINDING DOMAIN (RESIDUES 225 - 462)
|
Not recorded | REA RETINOIC ACID × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；295 K；20mM HEPES pH 7.5, 1.5M LiSO4, 10mM DTT, VAPOR DIFFUSION, HANGING DROP, temperature 295K
|
Resolution 2.00 Å R-free 0.254 |
| 1K74 The 2.3 Angstrom resolution crystal structure of the heterodimer of the human PPARgamma and RXRalpha ligand binding domains respectively bound with GW409544 and 9-cis retinoic acid and co-activator peptides. Deposited 2001-10-18 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain A
225–462（238 aa）
Fragment：ligand binding domain - residues 225 - 462
|
Not recorded | 9CR (9cis)-retinoic acid × 1 544 2-(1-METHYL-3-OXO-3-PHENYL-PROPYLAMINO)-3-{4-[2-(5-METHYL-2-PHENYL-OXAZOL-4-YL)-ETHOXY]-PHENYL}-PROPIONIC ACID × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；295 K；PEG4K, NaSCN, Ethylene Glycol, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 295K
|
Resolution 2.30 Å R-free 0.279 |
| 1MV9 Crystal Structure of the human RXR alpha ligand binding domain bound to the eicosanoid DHA (Docosa Hexaenoic Acid) and a coactivator peptide Deposited 2002-09-24 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain A
223–462（240 aa）
Fragment：ligand binding domain(residues 223-462)
|
Not recorded | HXA DOCOSA-4,7,10,13,16,19-HEXAENOIC ACID × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；295 K；PEG 4000, glycerol, NaCl, Pipes or BisTris, pH 7.0, VAPOR DIFFUSION, HANGING DROP, temperature 295K
|
Resolution 1.90 Å R-free 0.249 |
| 1MVC Crystal structure of the human RXR alpha ligand binding domain bound to the synthetic agonist compound BMS 649 and a coactivator peptide Deposited 2002-09-24 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain A
223–462（240 aa）
Fragment：ligand binding domain(residues 223-462)
|
Not recorded | BM6 4-[2-(5,5,8,8-TETRAMETHYL-5,6,7,8-TETRAHYDRO-NAPHTHALEN-2-YL)-[1,3]DIOXOLAN-2-YL]-BENZOIC ACID × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；295 K；PEG 4000, NaCl, Glycerol, BisTris, Pipes, pH 7.0, VAPOR DIFFUSION, HANGING DROP, temperature 295.0K
|
Resolution 1.90 Å R-free 0.228 |
| 1MZN CRYSTAL STRUCTURE at 1.9 ANGSTROEMS RESOLUTION OF THE HOMODIMER OF HUMAN RXR ALPHA LIGAND BINDING DOMAIN BOUND TO THE SYNTHETIC AGONIST COMPOUND BMS 649 AND A COACTIVATOR PEPTIDE Deposited 2002-10-09 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain A
223–462（240 aa）
Fragment：ligand binding domain(residues 223-462)
Chain C
223–462（240 aa）
Fragment：ligand binding domain(residues 223-462)
|
Not recorded | BM6 4-[2-(5,5,8,8-TETRAMETHYL-5,6,7,8-TETRAHYDRO-NAPHTHALEN-2-YL)-[1,3]DIOXOLAN-2-YL]-BENZOIC ACID × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；295 K；PEG 4000, NaCl, Pipes, BisTris, glycerol, pH 7, VAPOR DIFFUSION, HANGING DROP, temperature 295K
|
Resolution 1.90 Å R-free 0.232 |
| 1MZN CRYSTAL STRUCTURE at 1.9 ANGSTROEMS RESOLUTION OF THE HOMODIMER OF HUMAN RXR ALPHA LIGAND BINDING DOMAIN BOUND TO THE SYNTHETIC AGONIST COMPOUND BMS 649 AND A COACTIVATOR PEPTIDE Deposited 2002-10-09 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain E
223–462（240 aa）
Fragment：ligand binding domain(residues 223-462)
Chain G
223–462（240 aa）
Fragment：ligand binding domain(residues 223-462)
|
Not recorded | BM6 4-[2-(5,5,8,8-TETRAMETHYL-5,6,7,8-TETRAHYDRO-NAPHTHALEN-2-YL)-[1,3]DIOXOLAN-2-YL]-BENZOIC ACID × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；295 K；PEG 4000, NaCl, Pipes, BisTris, glycerol, pH 7, VAPOR DIFFUSION, HANGING DROP, temperature 295K
|
Resolution 1.90 Å R-free 0.232 |
| 1R0N Crystal Structure of Heterodimeric Ecdsyone receptor DNA binding complex Deposited 2003-09-22 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein–DNA Heteromer；Protein × 2 PDB declaration: tetrameric |
Chain A
130–206（77 aa）
Fragment：Retinoid X Receptor DNA binding domain
|
Not recorded | ZN ZINC ION × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 5.6；282 K；PEG 3350, Lithium Sulfate, Magnesium Sulfate, DTT, Magnesium Chloride, MES, pH 5.6, VAPOR DIFFUSION, temperature 282K
|
Resolution 2.60 Å R-free 0.292 |
| 1RDT Crystal Structure of a new rexinoid bound to the RXRalpha ligand binding doamin in the RXRalpha/PPARgamma heterodimer Deposited 2003-11-06 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain A
225–462（238 aa）
Fragment：ligand binding doamin
|
Not recorded | L79 (S)-(2E)-3[4-(5,5,8,8-TETRAMETHYL-5,6,7,8-TETRAHYDRO-2-NAPHTHALENYL)TETRAHYDRO-1-BENZOFURAN-2-YL]-2-PROPENOIC ACID × 1 570 2-(2-BENZOYL-PHENYLAMINO)-3-{4-[2-(5-METHYL-2-PHENYL-OXAZOL-4-YL)-ETHOXY]-PHENYL}-PROPIONIC ACID × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7.5；295 K；17% PEG 4K, 200mM NaSCN, 8% ethylene glycol, 8% glycerol, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 295K, pH 7.50
|
Resolution 2.40 Å R-free 0.259 |
| 1XLS Crystal structure of the mouse CAR/RXR LBD heterodimer bound to TCPOBOP and 9cRA and a TIF2 peptide containg the third LXXLL motifs Deposited 2004-09-30 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain A
227–458（232 aa）
Fragment：CAR LBD
|
Mutation：residues 116-238 | 9CR (9cis)-retinoic acid × 1 TCD 3,5-DICHLORO-2-{4-[(3,5-DICHLOROPYRIDIN-2-YL)OXY]PHENOXY}PYRIDINE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；295 K；10% PEG2K, 3% 1,6 hexanediol, 0.1 M di-ammonium tartrate, pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 295K
|
Resolution 2.96 Å R-free 0.303 |
| 1XLS Crystal structure of the mouse CAR/RXR LBD heterodimer bound to TCPOBOP and 9cRA and a TIF2 peptide containg the third LXXLL motifs Deposited 2004-09-30 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain B
227–458（232 aa）
Fragment：CAR LBD
|
Mutation：residues 116-238 | 9CR (9cis)-retinoic acid × 1 TCD 3,5-DICHLORO-2-{4-[(3,5-DICHLOROPYRIDIN-2-YL)OXY]PHENOXY}PYRIDINE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；295 K；10% PEG2K, 3% 1,6 hexanediol, 0.1 M di-ammonium tartrate, pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 295K
|
Resolution 2.96 Å R-free 0.303 |
| 1XLS Crystal structure of the mouse CAR/RXR LBD heterodimer bound to TCPOBOP and 9cRA and a TIF2 peptide containg the third LXXLL motifs Deposited 2004-09-30 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 3 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain C
227–458（232 aa）
Fragment：CAR LBD
|
Mutation：residues 116-238 | 9CR (9cis)-retinoic acid × 1 TCD 3,5-DICHLORO-2-{4-[(3,5-DICHLOROPYRIDIN-2-YL)OXY]PHENOXY}PYRIDINE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；295 K；10% PEG2K, 3% 1,6 hexanediol, 0.1 M di-ammonium tartrate, pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 295K
|
Resolution 2.96 Å R-free 0.303 |
| 1XLS Crystal structure of the mouse CAR/RXR LBD heterodimer bound to TCPOBOP and 9cRA and a TIF2 peptide containg the third LXXLL motifs Deposited 2004-09-30 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 4 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain D
227–458（232 aa）
Fragment：CAR LBD
|
Mutation：residues 116-238 | 9CR (9cis)-retinoic acid × 1 TCD 3,5-DICHLORO-2-{4-[(3,5-DICHLOROPYRIDIN-2-YL)OXY]PHENOXY}PYRIDINE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；295 K；10% PEG2K, 3% 1,6 hexanediol, 0.1 M di-ammonium tartrate, pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 295K
|
Resolution 2.96 Å R-free 0.303 |
| 1XLS Crystal structure of the mouse CAR/RXR LBD heterodimer bound to TCPOBOP and 9cRA and a TIF2 peptide containg the third LXXLL motifs Deposited 2004-09-30 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 5 Protein heterocomplex Heteromer；Protein × 16 PDB declaration: hexadecameric |
Chain A
227–458（232 aa）
Fragment：CAR LBD
Chain B
227–458（232 aa）
Fragment：CAR LBD
Chain C
227–458（232 aa）
Fragment：CAR LBD
Chain D
227–458（232 aa）
Fragment：CAR LBD
|
Mutation：residues 116-238 Mutation：residues 116-238 Mutation：residues 116-238 Mutation：residues 116-238 | 9CR (9cis)-retinoic acid × 4 TCD 3,5-DICHLORO-2-{4-[(3,5-DICHLOROPYRIDIN-2-YL)OXY]PHENOXY}PYRIDINE × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；295 K；10% PEG2K, 3% 1,6 hexanediol, 0.1 M di-ammonium tartrate, pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 295K
|
Resolution 2.96 Å R-free 0.303 |
| 1XLS Crystal structure of the mouse CAR/RXR LBD heterodimer bound to TCPOBOP and 9cRA and a TIF2 peptide containg the third LXXLL motifs Deposited 2004-09-30 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 6 Protein heterocomplex Heteromer；Protein × 8 PDB declaration: octameric |
Chain A
227–458（232 aa）
Fragment：CAR LBD
Chain C
227–458（232 aa）
Fragment：CAR LBD
|
Mutation：residues 116-238 Mutation：residues 116-238 | 9CR (9cis)-retinoic acid × 2 TCD 3,5-DICHLORO-2-{4-[(3,5-DICHLOROPYRIDIN-2-YL)OXY]PHENOXY}PYRIDINE × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；295 K；10% PEG2K, 3% 1,6 hexanediol, 0.1 M di-ammonium tartrate, pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 295K
|
Resolution 2.96 Å R-free 0.303 |
| 1XLS Crystal structure of the mouse CAR/RXR LBD heterodimer bound to TCPOBOP and 9cRA and a TIF2 peptide containg the third LXXLL motifs Deposited 2004-09-30 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 7 Protein heterocomplex Heteromer；Protein × 8 PDB declaration: octameric |
Chain B
227–458（232 aa）
Fragment：CAR LBD
Chain D
227–458（232 aa）
Fragment：CAR LBD
|
Mutation：residues 116-238 Mutation：residues 116-238 | 9CR (9cis)-retinoic acid × 2 TCD 3,5-DICHLORO-2-{4-[(3,5-DICHLOROPYRIDIN-2-YL)OXY]PHENOXY}PYRIDINE × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；295 K；10% PEG2K, 3% 1,6 hexanediol, 0.1 M di-ammonium tartrate, pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 295K
|
Resolution 2.96 Å R-free 0.303 |
| 1XV9 crystal structure of CAR/RXR heterodimer bound with SRC1 peptide, fatty acid, and 5b-pregnane-3,20-dione. Deposited 2004-10-27 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain A
227–462（236 aa）
Fragment：LBD domain
|
Not recorded | F15 PENTADECANOIC ACID × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 4.9；298 K；potassium sodium phosphate, pH 4.9, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 2.70 Å R-free 0.239 |
| 1XV9 crystal structure of CAR/RXR heterodimer bound with SRC1 peptide, fatty acid, and 5b-pregnane-3,20-dione. Deposited 2004-10-27 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain C
227–462（236 aa）
Fragment：LBD domain
|
Not recorded | F15 PENTADECANOIC ACID × 1 CI2 (5BETA)-PREGNANE-3,20-DIONE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 4.9；298 K；potassium sodium phosphate, pH 4.9, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 2.70 Å R-free 0.239 |
| 1XVP crystal structure of CAR/RXR heterodimer bound with SRC1 peptide, fatty acid and CITCO Deposited 2004-10-28 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain A
227–462（236 aa）
Fragment：LBD domain
|
Not recorded | F15 PENTADECANOIC ACID × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；277 K；Lisium sulphate, pH 8.0, VAPOR DIFFUSION, HANGING DROP, temperature 277K
|
Resolution 2.60 Å R-free 0.234 |
| 1XVP crystal structure of CAR/RXR heterodimer bound with SRC1 peptide, fatty acid and CITCO Deposited 2004-10-28 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain C
227–462（236 aa）
Fragment：LBD domain
|
Not recorded | F15 PENTADECANOIC ACID × 1 CID 6-(4-CHLOROPHENYL)IMIDAZO[2,1-B][1,3]THIAZOLE-5-CARBALDEHYDE O-(3,4-DICHLOROBENZYL)OXIME × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；277 K；Lisium sulphate, pH 8.0, VAPOR DIFFUSION, HANGING DROP, temperature 277K
|
Resolution 2.60 Å R-free 0.234 |
| 1XVP crystal structure of CAR/RXR heterodimer bound with SRC1 peptide, fatty acid and CITCO Deposited 2004-10-28 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 3 Protein heterocomplex Heteromer；Protein × 8 PDB declaration: octameric |
Chain A
227–462（236 aa）
Fragment：LBD domain
Chain C
227–462（236 aa）
Fragment：LBD domain
|
Not recorded | F15 PENTADECANOIC ACID × 2 CID 6-(4-CHLOROPHENYL)IMIDAZO[2,1-B][1,3]THIAZOLE-5-CARBALDEHYDE O-(3,4-DICHLOROBENZYL)OXIME × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；277 K；Lisium sulphate, pH 8.0, VAPOR DIFFUSION, HANGING DROP, temperature 277K
|
Resolution 2.60 Å R-free 0.234 |
| 1XVP crystal structure of CAR/RXR heterodimer bound with SRC1 peptide, fatty acid and CITCO Deposited 2004-10-28 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 4 Protein heterocomplex Heteromer；Protein × 6 PDB declaration: hexameric |
Chain A
227–462（236 aa）
Fragment：LBD domain
Chain C
227–462（236 aa）
Fragment：LBD domain
|
Not recorded | F15 PENTADECANOIC ACID × 2 CID 6-(4-CHLOROPHENYL)IMIDAZO[2,1-B][1,3]THIAZOLE-5-CARBALDEHYDE O-(3,4-DICHLOROBENZYL)OXIME × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；277 K；Lisium sulphate, pH 8.0, VAPOR DIFFUSION, HANGING DROP, temperature 277K
|
Resolution 2.60 Å R-free 0.234 |
| 1XVP crystal structure of CAR/RXR heterodimer bound with SRC1 peptide, fatty acid and CITCO Deposited 2004-10-28 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 5 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain A
227–462（236 aa）
Fragment：LBD domain
Chain C
227–462（236 aa）
Fragment：LBD domain
|
Not recorded | F15 PENTADECANOIC ACID × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；277 K；Lisium sulphate, pH 8.0, VAPOR DIFFUSION, HANGING DROP, temperature 277K
|
Resolution 2.60 Å R-free 0.234 |
| 1YNW Crystal Structure of Vitamin D Receptor and 9-cis Retinoic Acid Receptor DNA-Binding Domains Bound to a DR3 Response Element Deposited 2005-01-25 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein–DNA Heteromer；Protein × 2 PDB declaration: tetrameric |
Chain B
130–228（99 aa）
Fragment：DNA-binding Domain (Residues 130-228)
|
Not recorded | ZN ZINC ION × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；291 K；PEG 8000, ammonium citrate, Tris, glycerol, DTT, pH 8.5, VAPOR DIFFUSION, HANGING DROP, temperature 291K
|
Resolution 3.00 Å R-free 0.283 |
| 2ACL Liver X-Receptor alpha Ligand Binding Domain with SB313987 Deposited 2005-07-19 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
225–462（238 aa）
|
Not recorded | REA RETINOIC ACID × 1 L05 1-BENZYL-3-(4-METHOXYPHENYLAMINO)-4-PHENYLPYRROLE-2,5-DIONE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；298 K；PEG3350, Ammonium Acetate, BisTris, Dtt, pH 6.5, VAPOR DIFFUSION, SITTING DROP, temperature 298K
|
Resolution 2.80 Å R-free 0.280 |
| 2ACL Liver X-Receptor alpha Ligand Binding Domain with SB313987 Deposited 2005-07-19 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain C
225–462（238 aa）
|
Not recorded | REA RETINOIC ACID × 1 L05 1-BENZYL-3-(4-METHOXYPHENYLAMINO)-4-PHENYLPYRROLE-2,5-DIONE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；298 K；PEG3350, Ammonium Acetate, BisTris, Dtt, pH 6.5, VAPOR DIFFUSION, SITTING DROP, temperature 298K
|
Resolution 2.80 Å R-free 0.280 |
| 2ACL Liver X-Receptor alpha Ligand Binding Domain with SB313987 Deposited 2005-07-19 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 3 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain E
225–462（238 aa）
|
Not recorded | REA RETINOIC ACID × 1 L05 1-BENZYL-3-(4-METHOXYPHENYLAMINO)-4-PHENYLPYRROLE-2,5-DIONE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；298 K；PEG3350, Ammonium Acetate, BisTris, Dtt, pH 6.5, VAPOR DIFFUSION, SITTING DROP, temperature 298K
|
Resolution 2.80 Å R-free 0.280 |
| 2ACL Liver X-Receptor alpha Ligand Binding Domain with SB313987 Deposited 2005-07-19 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 4 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain G
225–462（238 aa）
|
Not recorded | REA RETINOIC ACID × 1 L05 1-BENZYL-3-(4-METHOXYPHENYLAMINO)-4-PHENYLPYRROLE-2,5-DIONE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；298 K；PEG3350, Ammonium Acetate, BisTris, Dtt, pH 6.5, VAPOR DIFFUSION, SITTING DROP, temperature 298K
|
Resolution 2.80 Å R-free 0.280 |
| 2ACL Liver X-Receptor alpha Ligand Binding Domain with SB313987 Deposited 2005-07-19 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 5 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain C
225–462（238 aa）
Chain G
225–462（238 aa）
|
Not recorded | REA RETINOIC ACID × 2 L05 1-BENZYL-3-(4-METHOXYPHENYLAMINO)-4-PHENYLPYRROLE-2,5-DIONE × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；298 K；PEG3350, Ammonium Acetate, BisTris, Dtt, pH 6.5, VAPOR DIFFUSION, SITTING DROP, temperature 298K
|
Resolution 2.80 Å R-free 0.280 |
| 2ACL Liver X-Receptor alpha Ligand Binding Domain with SB313987 Deposited 2005-07-19 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 6 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain A
225–462（238 aa）
Chain E
225–462（238 aa）
|
Not recorded | REA RETINOIC ACID × 2 L05 1-BENZYL-3-(4-METHOXYPHENYLAMINO)-4-PHENYLPYRROLE-2,5-DIONE × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；298 K；PEG3350, Ammonium Acetate, BisTris, Dtt, pH 6.5, VAPOR DIFFUSION, SITTING DROP, temperature 298K
|
Resolution 2.80 Å R-free 0.280 |
| 2NLL RETINOID X RECEPTOR-THYROID HORMONE RECEPTOR DNA-BINDING DOMAIN HETERODIMER BOUND TO THYROID RESPONSE ELEMENT DNA Deposited 1996-11-20 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein–DNA Heteromer；Protein × 2 PDB declaration: tetrameric |
Chain A
135–200（66 aa）
|
Not recorded | ZN ZINC ION × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7；CRYSTALLIZED FROM 40% PEG 3350 25 MM IMADAZOLE BUFFER, PH 7.0, 400 MM NH4CL, 10 MM DTT, AND 5 MM MGCL2
|
Resolution 1.90 Å R-free 0.269 |
| 2P1T Crystal structure of the ligand binding domain of the retinoid X receptor alpha in complex with 3-(2'-methoxy)-tetrahydronaphtyl cinnamic acid and a fragment of the coactivator TIF-2 Deposited 2007-03-06 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain A
223–462（240 aa）
Fragment：ligand binding domain (residues 223-462)
|
Not recorded | 3TN (2E)-3-[4-HYDROXY-3-(3-METHOXY-5,5,8,8-TETRAMETHYL-5,6,7,8-TETRAHYDRONAPHTHALEN-2-YL)PHENYL]ACRYLIC ACID × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；298 K；16% PEG 3350, 0.1M Tris, 1M ammonium acetate, pH 8.5, VAPOR DIFFUSION, HANGING DROP, temperature 298.0K
|
Resolution 1.80 Å R-free 0.218 |
| 2P1U Crystal structure of the ligand binding domain of the retinoid X receptor alpha in complex with 3-(2'-ethoxy)-tetrahydronaphtyl cinnamic acid and a fragment of the coactivator TIF-2 Deposited 2007-03-06 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain A
223–462（240 aa）
Fragment：ligand binding domain (residues 223-462)
|
Not recorded | 4TN (2E)-3-[3-(3-ETHOXY-5,5,8,8-TETRAMETHYL-5,6,7,8-TETRAHYDRONAPHTHALEN-2-YL)-4-HYDROXYPHENYL]ACRYLIC ACID × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；298 K；14% PEG 10000, 0.1M Tris, 1M ammonium chloride, pH 8.5, VAPOR DIFFUSION, SITTING DROP, temperature 298K
|
Resolution 2.20 Å R-free 0.251 |
| 2P1V Crystal structure of the ligand binding domain of the retinoid X receptor alpha in complex with 3-(2'-propoxy)-tetrahydronaphtyl cinnamic acid and a fragment of the coactivator TIF-2 Deposited 2007-03-06 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain A
223–462（240 aa）
Fragment：ligand binding domain (residues 223-462)
|
Not recorded | 5TN (2E)-3-[4-HYDROXY-3-(5,5,8,8-TETRAMETHYL-3-PROPOXY-5,6,7,8-TETRAHYDRONAPHTHALEN-2-YL)PHENYL]ACRYLIC ACID × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；298 K；24% PEG 4000, 0.1M Tris, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 2.20 Å R-free 0.232 |
| 2ZXZ Crystal structure of the human RXR alpha ligand binding domain bound to a synthetic agonist compound and a coactivator peptide Deposited 2009-01-09 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain A
223–462（240 aa）
Fragment：Ligand Binding Domain
|
Not recorded | P26 4-[2-(1,1,3,3-tetramethyl-2,3-dihydro-1H-inden-5-yl)-1,3-dioxolan-2-yl]benzoic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；290 K；10mM Tris-HCl, 250mM NaCl, 5mM DTT, 50mM calcium acetate, 18% PEG3350, pH 8.0, VAPOR DIFFUSION, HANGING DROP, temperature 290K
|
Resolution 3.00 Å R-free 0.278 |
| 2ZY0 Crystal structure of the human RXR alpha ligand binding domain bound to a synthetic agonist compound and a coactivator peptide Deposited 2009-01-09 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain A
223–462（240 aa）
Fragment：Ligand Binding Domain
Chain C
223–462（240 aa）
Fragment：Ligand Binding Domain
|
Not recorded | 21P 4-[2-(1,1,3,3-tetramethyl-2,3-dihydro-1H-1,3-benzodisilol-5-yl)-1,3-dioxolan-2-yl]benzoic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；290 K；10mM Tris-HCl, 250mM NaCl, 5mM DTT, 50mM calcium acetate, 18% PEG3350, pH 8.0, VAPOR DIFFUSION, HANGING DROP, temperature 290K
|
Resolution 2.90 Å R-free 0.289 |
| 3DZU Intact PPAR gamma - RXR alpha Nuclear Receptor Complex on DNA bound with BVT.13, 9-cis Retinoic Acid and NCOA2 Peptide Deposited 2008-07-30 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein–DNA Heteromer；Protein × 4 PDB declaration: hexameric |
Chain A
11–462（452 aa）
Fragment：UNP residues 11-462
|
Not recorded | ZN ZINC ION × 4 9CR (9cis)-retinoic acid × 1 PLB 2-[(2,4-DICHLOROBENZOYL)AMINO]-5-(PYRIMIDIN-2-YLOXY)BENZOIC ACID × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；277 K；15-18% PEG 3350, 25mM MgCl2, 100mM NH4Cl, 5mM DTT and 0.1M MES, pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 277K
|
Resolution 3.20 Å R-free 0.272 |
| 3DZY Intact PPAR gamma - RXR alpha Nuclear Receptor Complex on DNA bound with Rosiglitazone, 9-cis Retinoic Acid and NCOA2 Peptide Deposited 2008-07-30 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein–DNA Heteromer；Protein × 4 PDB declaration: hexameric |
Chain A
11–462（452 aa）
Fragment：UNP residues 11-462
|
Not recorded | 9CR (9cis)-retinoic acid × 1 ZN ZINC ION × 4 BRL 2,4-THIAZOLIDIINEDIONE, 5-[[4-[2-(METHYL-2-PYRIDINYLAMINO)ETHOXY]PHENYL]METHYL]-(9CL) × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；277 K；15-18% PEG 3350, 25mM MgCl2, 100mM NH4Cl, 5mM DTT and 0.1M MES, pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 277K
|
Resolution 3.10 Å R-free 0.268 |
| 3E00 Intact PPAR gamma - RXR alpha Nuclear Receptor Complex on DNA bound with GW9662, 9-cis Retinoic Acid and NCOA2 Peptide Deposited 2008-07-30 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein–DNA Heteromer；Protein × 4 PDB declaration: hexameric |
Chain A
11–462（452 aa）
Fragment：UNP residues 11-462
|
Not recorded | ZN ZINC ION × 4 9CR (9cis)-retinoic acid × 1 GW9 2-chloro-5-nitro-N-phenylbenzamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；277 K；15-18% PEG 3350, 25mM MgCl2, 100mM NH4Cl, 5mM DTT and 0.1M MES, pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 277K
|
Resolution 3.10 Å R-free 0.276 |
| 3E94 Crystal structure of RXRalpha ligand binding domain in complex with tributyltin and a coactivator fragment Deposited 2008-08-21 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain A
223–462（240 aa）
Fragment：ligand binding domain (UNP residues 223-462)
|
Not recorded | TBY tributylstannanyl × 2 ACT ACETATE ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 7.5；293 K；PEG 4000, ammonium acetate, pH 7.5, VAPOR DIFFUSION, temperature 293K
|
Resolution 1.90 Å R-free 0.225 |
| 3FAL humanRXR alpha & mouse LXR alpha complexed with Retenoic acid and GSK2186 Deposited 2008-11-17 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain A
225–462（238 aa）
Fragment：residues 225-462
Chain C
225–462（238 aa）
Fragment：residues 225-462
|
Not recorded | REA RETINOIC ACID × 2 LO2 2-{4-[butyl(3-chloro-4,5-dimethoxybenzyl)amino]phenyl}-1,1,1,3,3,3-hexafluoropropan-2-ol × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；3uL 6.6mgs/ml protein + 3 uL well containing 21 % - 23 % PEG 3550, 200mM Ammonium Acetate, 100 mM Bis Tris pH 6.5 and 10 mM DTT, VAPOR DIFFUSION, SITTING DROP
|
Resolution 2.36 Å R-free 0.278 |
| 3FAL humanRXR alpha & mouse LXR alpha complexed with Retenoic acid and GSK2186 Deposited 2008-11-17 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
225–462（238 aa）
Fragment：residues 225-462
|
Not recorded | REA RETINOIC ACID × 1 LO2 2-{4-[butyl(3-chloro-4,5-dimethoxybenzyl)amino]phenyl}-1,1,1,3,3,3-hexafluoropropan-2-ol × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；3uL 6.6mgs/ml protein + 3 uL well containing 21 % - 23 % PEG 3550, 200mM Ammonium Acetate, 100 mM Bis Tris pH 6.5 and 10 mM DTT, VAPOR DIFFUSION, SITTING DROP
|
Resolution 2.36 Å R-free 0.278 |
| 3FAL humanRXR alpha & mouse LXR alpha complexed with Retenoic acid and GSK2186 Deposited 2008-11-17 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 3 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain C
225–462（238 aa）
Fragment：residues 225-462
|
Not recorded | REA RETINOIC ACID × 1 LO2 2-{4-[butyl(3-chloro-4,5-dimethoxybenzyl)amino]phenyl}-1,1,1,3,3,3-hexafluoropropan-2-ol × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；3uL 6.6mgs/ml protein + 3 uL well containing 21 % - 23 % PEG 3550, 200mM Ammonium Acetate, 100 mM Bis Tris pH 6.5 and 10 mM DTT, VAPOR DIFFUSION, SITTING DROP
|
Resolution 2.36 Å R-free 0.278 |
| 3FC6 hRXRalpha & mLXRalpha with an indole Pharmacophore, SB786875 Deposited 2008-11-21 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain A
225–462（238 aa）
Chain C
225–462（238 aa）
|
Not recorded | REA RETINOIC ACID × 2 LX2 [4-(3-{[2-chloro-3-(trifluoromethyl)benzyl](2,2-diphenylethyl)amino}propoxy)-1H-indol-1-yl]acetic acid × 2 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 2.06 Å R-free 0.250 |
| 3FUG Crystal Structure of the Retinoid X Receptor Ligand Binding Domain Bound to the Synthetic Agonist 3-[4-Hydroxy-3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)-phenyl]acrylic Acid Deposited 2009-01-14 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
223–462（240 aa）
Fragment：LIGAND BINDING DOMAIN (RESIDUES 223-462)
|
Not recorded | 2E3 (2E)-3-[4-hydroxy-3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)phenyl]prop-2-enoic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；298 K；20% PEG 4000, 0.1M TRIS, 1M AMMONIUM ACETATE, pH 8.0, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 2.00 Å R-free 0.241 |
| 3FUG Crystal Structure of the Retinoid X Receptor Ligand Binding Domain Bound to the Synthetic Agonist 3-[4-Hydroxy-3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)-phenyl]acrylic Acid Deposited 2009-01-14 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain A
223–462（240 aa）
Fragment：LIGAND BINDING DOMAIN (RESIDUES 223-462)
|
Not recorded | 2E3 (2E)-3-[4-hydroxy-3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)phenyl]prop-2-enoic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；298 K；20% PEG 4000, 0.1M TRIS, 1M AMMONIUM ACETATE, pH 8.0, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 2.00 Å R-free 0.241 |
| 3H0A Crystal Structure of Peroxisome Proliferator-Activated Receptor Gamma (PPARg) and Retinoic Acid Receptor Alpha (RXRa) in Complex with 9-cis Retinoic Acid, Co-activator Peptide, and a Partial Agonist Deposited 2009-04-08 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain A
228–455（228 aa）
Fragment：UNP RESIDUES 228-455
|
Not recorded | 9RA 4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)ethenyl]benzoic acid × 1 D30 [(4-{[2-(pent-2-yn-1-yloxy)-4-{[4-(trifluoromethyl)phenoxy]methyl}phenyl]sulfanyl}-5,6,7,8-tetrahydronaphthalen-1-yl)oxy]acetic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 7.5；289 K；25% PEG 2000 monomethyl ether, 0.3 M sodium acetate, 0.1 M Hepes 7.5, vapor diffusion, temperature 289K
|
Resolution 2.10 Å R-free 0.342 |
| 3KWY Crystal structure of RXRalpha ligand binding domain in complex with triphenyltin and a coactivator fragment Deposited 2009-12-02 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain A
223–462（240 aa）
Fragment：ligand binding domain
|
Not recorded | T9T triphenylstannanyl × 2 ACT ACETATE ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 7.5；293 K；PEG 4000, acetate ammonium, Tris-HCl, pH 7.5, VAPOR DIFFUSION, temperature 293K
|
Resolution 2.30 Å R-free 0.244 |
| 3OAP Crystal structure of human Retinoid X Receptor alpha-ligand binding domain complex with 9-cis retinoic acid and the coactivator peptide GRIP-1 Deposited 2010-08-05 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain A
228–458（231 aa）
Fragment：hRXRalpha-LBD, UNP residues 228-458
|
Not recorded | 9CR (9cis)-retinoic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；296 K；4-20% PEG4000, 4-16% glycerol, 0.1M Bis-Tris, pH7.0, VAPOR DIFFUSION, HANGING DROP, temperature 296K
|
Resolution 2.05 Å R-free 0.244 |
| 3OZJ Crystal structure of human retinoic X receptor alpha complexed with bigelovin and coactivator SRC-1 Deposited 2010-09-25 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain A
225–462（238 aa）
Fragment：ligand-binding domain, UNP residues 225-462
Chain C
225–462（238 aa）
Fragment：ligand-binding domain, UNP residues 225-462
|
Not recorded | BGV (3aR,4S,4aR,7aR,8R,9aS)-4a,8-dimethyl-3-methylidene-2,5-dioxo-2,3,3a,4,4a,5,7a,8,9,9a-decahydroazuleno[6,5-b]furan-4-yl acetate × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；277 K；8% v/v Tacsimate pH7.5, 20% w/v PEG3350, VAPOR DIFFUSION, HANGING DROP, temperature 277K
|
Resolution 2.10 Å |
| 3PCU Crystal structure of human retinoic X receptor alpha ligand-binding domain complexed with LX0278 and SRC1 peptide Deposited 2010-10-22 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain A
229–458（230 aa）
Fragment：UNP residues 229-458
|
Not recorded | LX8 2-[(2S)-6-(2-methylbut-3-en-2-yl)-7-oxo-2,3-dihydro-7H-furo[3,2-g]chromen-2-yl]propan-2-yl acetate × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；277 K；8% v/v Tacsimate pH8.0, 20% w/v PEG 3350, VAPOR DIFFUSION, HANGING DROP, temperature 277K
|
Resolution 2.00 Å |
| 3R29 Crystal structure of RXRalpha ligand-binding domain complexed with corepressor SMRT2 Deposited 2011-03-14 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 8 PDB declaration: octameric |
Chain A
223–462（240 aa）
Fragment：ligand binding domain (UNP residues 223-462)
Chain B
223–462（240 aa）
Fragment：ligand binding domain (UNP residues 223-462)
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；293 K；100 mM sodium cacodylate, 15% PEG4000, 100 mM magnesium acetate, pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.90 Å R-free 0.326 |
| 3R2A Crystal structure of RXRalpha ligand-binding domain complexed with corepressor SMRT2 and antagonist rhein Deposited 2011-03-14 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 6 PDB declaration: hexameric |
Chain A
223–462（240 aa）
Fragment：ligand binding domain (UNP residues 223-462)
Chain B
223–462（240 aa）
Fragment：ligand binding domain (UNP residues 223-462)
Chain C
223–462（240 aa）
Fragment：ligand binding domain (UNP residues 223-462)
Chain D
223–462（240 aa）
Fragment：ligand binding domain (UNP residues 223-462)
|
Not recorded | RHN 4,5-dihydroxy-9,10-dioxo-9,10-dihydroanthracene-2-carboxylic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；293 K；100 mM sodium cacodylate, 20% PEG4000, 100 mM magnesium acetate, pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 3.00 Å R-free 0.335 |
| 3R5M Crystal structure of RXRalphaLBD complexed with the agonist magnolol Deposited 2011-03-18 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain A
223–462（240 aa）
Fragment：ligand binding domain (UNP residues 223-462)
Chain C
223–462（240 aa）
Fragment：ligand binding domain (UNP residues 223-462)
|
Not recorded | MLO 5,5'-di(prop-2-en-1-yl)biphenyl-2,2'-diol × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；277 K；20% PEG3350, 100 mM Tris, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 277K
|
Resolution 2.80 Å R-free 0.293 |
| 3UVV Crystal Structure of the ligand binding domains of the thyroid receptor:retinoid X receptor complexed with 3,3',5 triiodo-L-thyronine and 9-cis retinoic acid Deposited 2011-11-30 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain B
225–462（238 aa）
Fragment：ligand binding domain (UNP Residues 225-462)
|
Not recorded | T3 3,5,3'TRIIODOTHYRONINE × 1 9CR (9cis)-retinoic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.3；298 K；100 mM HEPES (pH 7.3), 200 mM Tri-Sodium citrate dihydrate, 15% Isopropanol, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 2.95 Å R-free 0.250 |
| 4CN2 Crystal Structure of the Human Retinoid X Receptor DNA-Binding Domain Bound to the Human Ramp2 Response Element Deposited 2014-01-21 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein–DNA Homooligomer；Protein × 2 PDB declaration: tetrameric |
Chain C
130–212（83 aa）
Fragment：DNA-BINDING DOMAIN, RESIDUES 130-212
Chain D
130–212（83 aa）
Fragment：DNA-BINDING DOMAIN, RESIDUES 130-212
|
Not recorded | MG MAGNESIUM ION × 7 ZN ZINC ION × 4 MES 2-(N-MORPHOLINO)-ETHANESULFONIC ACID × 1 CL CHLORIDE ION × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 6；20% PEG 3350, 0.2M NH4CL, 0.1M MGCL2, 0.1M MES PH 6
|
Resolution 2.07 Å R-free 0.214 |
| 4CN3 Crystal Structure of the Human Retinoid X Receptor DNA-Binding Domain Bound to the Human Gde1SpA Response Element Deposited 2014-01-21 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein–DNA Homooligomer；Protein × 2 PDB declaration: tetrameric |
Chain B
130–212（83 aa）
Fragment：DNA-BINDING DOMAIN, RESIDUES 130-212
Chain C
130–212（83 aa）
Fragment：DNA-BINDING DOMAIN, RESIDUES 130-212
|
Not recorded | ZN ZINC ION × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 6.11；20% PEG 3350, 0.2M NH4CL, pH 6.11
|
Resolution 2.35 Å R-free 0.249 |
| 4CN3 Crystal Structure of the Human Retinoid X Receptor DNA-Binding Domain Bound to the Human Gde1SpA Response Element Deposited 2014-01-21 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein–DNA Homooligomer；Protein × 2 PDB declaration: tetrameric |
Chain A
130–212（83 aa）
Fragment：DNA-BINDING DOMAIN, RESIDUES 130-212
Chain D
130–212（83 aa）
Fragment：DNA-BINDING DOMAIN, RESIDUES 130-212
|
Not recorded | ZN ZINC ION × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 6.11；20% PEG 3350, 0.2M NH4CL, pH 6.11
|
Resolution 2.35 Å R-free 0.249 |
| 4CN5 Crystal Structure of the Human Retinoid X Receptor DNA-Binding Domain Bound to the Human Nr1d1 Response Element Deposited 2014-01-21 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein–DNA Homooligomer；Protein × 2 PDB declaration: tetrameric |
Chain A
130–212（83 aa）
Fragment：DNA-BINDING DOMAIN, RESIDUES 126-212
Chain B
130–212（83 aa）
Fragment：DNA-BINDING DOMAIN, RESIDUES 126-212
|
Not recorded | ZN ZINC ION × 4 CL CHLORIDE ION × 5 K POTASSIUM ION × 4 NO3 NITRATE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 6.6；20% PEG 3350, 0.2M KNO3, pH 6.6
|
Resolution 2.00 Å R-free 0.227 |
| 4CN7 Crystal Structure of the Human Retinoid X Receptor DNA-Binding Domain Bound to an idealized DR1 Response Element Deposited 2014-01-21 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein–DNA Homooligomer；Protein × 2 PDB declaration: tetrameric |
Chain E
130–212（83 aa）
Fragment：DNA-BINDING DOMAIN, RESIDUES 130-212
Chain F
130–212（83 aa）
Fragment：DNA-BINDING DOMAIN, RESIDUES 130-212
|
Not recorded | ZN ZINC ION × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7；20% PEG 3350, 0.1M NH4CL, 0.1M MGCL2, 0.1M MOPS PH 7
|
Resolution 2.34 Å R-free 0.209 |
| 4CN7 Crystal Structure of the Human Retinoid X Receptor DNA-Binding Domain Bound to an idealized DR1 Response Element Deposited 2014-01-21 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein–DNA Homooligomer；Protein × 2 PDB declaration: tetrameric |
Chain A
130–212（83 aa）
Fragment：DNA-BINDING DOMAIN, RESIDUES 130-212
Chain B
130–212（83 aa）
Fragment：DNA-BINDING DOMAIN, RESIDUES 130-212
|
Not recorded | ZN ZINC ION × 4 CL CHLORIDE ION × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7；20% PEG 3350, 0.1M NH4CL, 0.1M MGCL2, 0.1M MOPS PH 7
|
Resolution 2.34 Å R-free 0.209 |
| 4J5W Crystal Structure of the apo-PXR/RXRalpha LBD Heterotetramer Complex Deposited 2013-02-10 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Insufficient information Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain C
227–462（236 aa）
Chain D
227–462（236 aa）
|
Not recorded | MG MAGNESIUM ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；277.15 K；16-20% PEG 8000, 0.1-0.2 M MgCl, 0.1 M bis-tris proprane, 0.02% sodium azide, pH 7.0, vapor diffusion, hanging drop, temperature 277.15K
|
Resolution 2.80 Å R-free 0.298 |
| 4J5X Crystal Structure of the SR12813-bound PXR/RXRalpha LBD Heterotetramer Complex Deposited 2013-02-10 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Insufficient information Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain C
227–462（236 aa）
Chain D
227–462（236 aa）
|
Not recorded | SRL [2-(3,5-DI-TERT-BUTYL-4-HYDROXY-PHENYL)-1-(DIETHOXY-PHOSPHORYL)-VINYL]-PHOSPHONIC ACID DIETHLYL ESTER × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；277.15 K；16-20% PEG 8000, 0.1-0.2 M MgCl, 0.1 M bis-tris proprane, 0.02% sodium azide, pH 7.0, vapor diffusion, hanging drop, temperature 277.15K
|
Resolution 2.80 Å R-free 0.298 |
| 4K4J Crystal structure of human Retinoid X Receptor alpha-ligand binding domain complex with 9cUAB30 and the coactivator peptide GRIP-1 Deposited 2013-04-12 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain A
228–458（231 aa）
Fragment：ligand binding domain, UNP residues 228-458
|
Not recorded | 1O8 (2E,4E,6Z,8E)-8-(3,4-dihydronaphthalen-1(2H)-ylidene)-3,7-dimethylocta-2,4,6-trienoic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；295 K；5-10% PEG4000, 2-5% Glycerol, 0.1M Bis-Tris, pH 7, VAPOR DIFFUSION, HANGING DROP, temperature 295K
|
Resolution 2.00 Å R-free 0.283 |
| 4K6I Crystal structure of human retinoid X receptor alpha-ligand binding domain complex with Targretin and the coactivator peptide GRIP-1 Deposited 2013-04-15 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain A
228–458（231 aa）
Fragment：ligand binding domain, UNP residues 228-458
|
Not recorded | 9RA 4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)ethenyl]benzoic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；295 K；5-15% PEG4000, 6-12% Glycerol, 0.1M Bis-Tris pH 7.0, VAPOR DIFFUSION, HANGING DROP, temperature 295K
|
Resolution 2.10 Å R-free 0.288 |
| 4M8E CRYSTAL STRUCTURE OF HUMAN RETINOID X RECEPTOR ALPHA-LIGAND BINDING DOMAIN COMPLEX WITH (S) 4-Methyl 9cUAB30 COACTIVATOR PEPTIDE GRIP-1 Deposited 2013-08-13 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain A
228–458（231 aa）
Fragment：HRXRALPHA-LBD, UNP RESIDUES 228-458
|
Not recorded | 29V (3E,6Z,8E)-3,7-dimethyl-8-[(4S)-4-methyl-3,4-dihydronaphthalen-1(2H)-ylidene]octa-3,6-dienoic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；295 K；4-20% PEG4000, 4-16% GLYCEROL, 0.1M BIS-TRIS, PH7.0, VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 295K
|
Resolution 2.40 Å R-free 0.247 |
| 4M8H CRYSTAL STRUCTURE OF HUMAN RETINOID X RECEPTOR ALPHA-LIGAND BINDING DOMAIN COMPLEX WITH (R)4-METHYL 9cUAB30 AND COACTIVATOR PEPTIDE GRIP-1 Deposited 2013-08-13 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain A
228–458（231 aa）
Fragment：HRXRALPHA-LBD, UNP RESIDUES 228-458
|
Not recorded | R4M (2E,6Z,8E)-3,7-dimethyl-8-[(4R)-4-methyl-3,4-dihydronaphthalen-1(2H)-ylidene]octa-2,6-dienoic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；295 K；4-20% PEG4000, 4-16% GLYCEROL, 0.1M BIS-TRIS, PH7.0, VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 295K
|
Resolution 2.20 Å R-free 0.265 |
| 4N5G Crystal Structure of RXRa LBD complexed with a synthetic modulator K8012 Deposited 2013-10-09 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
223–462（240 aa）
Fragment：ligand binding domain (UNP residues 223-462)
Chain B
223–462（240 aa）
Fragment：ligand binding domain (UNP residues 223-462)
Chain C
223–462（240 aa）
Fragment：ligand binding domain (UNP residues 223-462)
Chain D
223–462（240 aa）
Fragment：ligand binding domain (UNP residues 223-462)
|
Not recorded | K09 5-(2-{(1Z)-5-fluoro-2-methyl-1-[4-(propan-2-yl)benzylidene]-1H-inden-3-yl}ethyl)-1H-tetrazole × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8；293 K；20% PEG3330, 0.2M Na Acetate, 100 mM NaCl, 20 mM Tris-Cl, 0.5 mM ligand K-8012, pH 8.0, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 2.11 Å R-free 0.247 |
| 4N8R Crystal structure of RXRa LBD complexed with a synthetic modulator K-8008 Deposited 2013-10-17 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
223–462（240 aa）
Fragment：ligand binding domain (UNP residues 223-462)
Chain B
223–462（240 aa）
Fragment：ligand binding domain (UNP residues 223-462)
Chain C
223–462（240 aa）
Fragment：ligand binding domain (UNP residues 223-462)
Chain D
223–462（240 aa）
Fragment：ligand binding domain (UNP residues 223-462)
|
Not recorded | K08 5-(2-{(1Z)-2-methyl-1-[4-(propan-2-yl)benzylidene]-1H-inden-3-yl}ethyl)-1H-tetrazole × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8；293 K；20% PEG3330, 0.2M Mg Formate, 100 MM NACL, 20 MM TRIS-CL, 0.5 MM LIGAND K-8008, pH 8.0, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 2.03 Å R-free 0.239 |
| 4NQA Crystal structure of liganded hRXR-alpha/hLXR-beta heterodimer on DNA Deposited 2013-11-24 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein–DNA Heteromer；Protein × 4 PDB declaration: hexameric |
Chain A
98–462（365 aa）
Fragment：UNP residues 98-462
|
Not recorded | 9CR (9cis)-retinoic acid × 1 ZN ZINC ION × 4 965 [3-(3-{[2-chloro-3-(trifluoromethyl)benzyl](2,2-diphenylethyl)amino}propoxy)phenyl]acetic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；295 K；6% PEG8000, 18% isopropanol, 0.05 M Tris, pH 8.0, VAPOR DIFFUSION, HANGING DROP, temperature 295K
|
Resolution 3.10 Å R-free 0.218 |
| 4NQA Crystal structure of liganded hRXR-alpha/hLXR-beta heterodimer on DNA Deposited 2013-11-24 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein–DNA Heteromer；Protein × 4 PDB declaration: hexameric |
Chain H
98–462（365 aa）
Fragment：UNP residues 98-462
|
Not recorded | 9CR (9cis)-retinoic acid × 1 ZN ZINC ION × 4 965 [3-(3-{[2-chloro-3-(trifluoromethyl)benzyl](2,2-diphenylethyl)amino}propoxy)phenyl]acetic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；295 K；6% PEG8000, 18% isopropanol, 0.05 M Tris, pH 8.0, VAPOR DIFFUSION, HANGING DROP, temperature 295K
|
Resolution 3.10 Å R-free 0.218 |
| 4OC7 Retinoic acid receptor alpha in complex with (E)-3-(3'-allyl-6-hydroxy-[1,1'-biphenyl]-3-yl)acrylic acid and a fragment of the coactivator TIF2 Deposited 2014-01-08 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain A
223–462（240 aa）
Fragment：ligand binding domain (UNP residues 223-462)
|
Not recorded | 2QO (2E)-3-[6-hydroxy-3'-(prop-2-en-1-yl)biphenyl-3-yl]prop-2-enoic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；277 K；0.1 M Na HEPES pH 7.5, 20% PEG 2000 MME, VAPOR DIFFUSION, HANGING DROP, temperature 277K
|
Resolution 2.50 Å R-free 0.242 |
| 4POH Crystal structure of human Retinoid X Receptor alpha-ligand binding domain complex with 8-methyl UAB30 and the coactivator peptide GRIP-1 Deposited 2014-02-25 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain A
228–458（231 aa）
Fragment：Ligand Binding Domain, UNP residues 228-458
|
Not recorded | 2VR (2E,4E,6Z,8E)-3,7-dimethyl-8-(8-methyl-3,4-dihydronaphthalen-1(2H)-ylidene)octa-2,4,6-trienoic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；295 K；4-12% PEG4000, 3-12% Glycerol, 0.1M Bis-Tris, pH 7.0, VAPOR DIFFUSION, HANGING DROP, temperature 295K
|
Resolution 2.30 Å R-free 0.265 |
| 4POJ Crystal structure of human Retinoid X Receptor alpha-ligand binding domain complex with 7-methyl UAB30 and the coactivator peptide GRIP-1 Deposited 2014-02-25 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain A
228–458（231 aa）
Fragment：Ligand Binding Domain, UNP residues 228-458
|
Not recorded | 2VP (2E,4E,6Z,8E)-3,7-dimethyl-8-(7-methyl-3,4-dihydronaphthalen-1(2H)-ylidene)octa-2,4,6-trienoic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；4-12% PEG4000, 3-12% Glycerol, 0.1M Bis-Tris, pH 7.0 , VAPOR DIFFUSION, HANGING DROP
|
Resolution 2.00 Å R-free 0.261 |
| 4PP3 Crystal structure of human Retinoid X Receptor alpha-ligand binding domain complex with 6-methyl UAB30 and the coactivator peptide GRIP-1 Deposited 2014-02-26 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain A
228–458（231 aa）
Fragment：Ligand Binding Domain, UNP residues 228-458
|
Not recorded | 2VZ (2E,4E,6Z,8E)-3,7-dimethyl-8-(6-methyl-3,4-dihydronaphthalen-1(2H)-ylidene)octa-2,4,6-trienoic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；295 K；4-12% PEG4000, 3-12% Glycerol, 0.1M Bis-Tris, pH 7.0, VAPOR DIFFUSION, HANGING DROP, temperature 295K
|
Resolution 2.00 Å R-free 0.275 |
| 4PP5 Crystal structure of human Retinoid X Receptor alpha-ligand binding domain complex with 5-methyl UAB30 and the coactivator peptide GRIP-1 Deposited 2014-02-26 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain A
228–458（231 aa）
Fragment：Ligand Binding Domain, UNP residues 228-458
|
Not recorded | 2W0 (2E,4E,6Z,8E)-3,7-dimethyl-8-(5-methyl-3,4-dihydronaphthalen-1(2H)-ylidene)octa-2,4,6-trienoic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；295 K；4-12% PEG4000, 3-12% Glycerol, 0.1M Bis-Tris, pH 7.0 , VAPOR DIFFUSION, HANGING DROP, temperature 295K
|
Resolution 2.00 Å R-free 0.250 |
| 4RFW Crystal structure of human retinoid X Receptor alpha-ligand binding domain complex with 9cUAB70 and the coactivator peptide GRIP-1 Deposited 2014-09-28 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain A
228–458（231 aa）
Fragment：ligand binding domain residues 228-458
|
Not recorded | 3RB (2E,4E,6Z,8E)-3,7-dimethyl-8-(6,7,8,9-tetrahydro-5H-benzo[7]annulen-5-ylidene)octa-2,4,6-trienoic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；295 K；5-12% PEG4000, 3-12 Glycerol, 0.1 Bis-Tris pH 7.0, VAPOR DIFFUSION, HANGING DROP, temperature 295K
|
Resolution 2.40 Å R-free 0.261 |
| 4RMC Crystal Structure of human retinoid X receptor alpha-ligand binding domain complex with 9cUAB76 and the coactivator peptide GRIP-1 Deposited 2014-10-21 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain A
228–458（231 aa）
Fragment：ligand binding domain 228-458
|
Not recorded | 3SV (3S,7S,8E)-8-[3-ethyl-2-(3-methylbutyl)cyclohex-2-en-1-ylidene]-3,7-dimethyloctanoic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；295 K；5-15% PEG4000, 4-12% Glycerol, 0.1M Bis-Tris, pH=7.0, VAPOR DIFFUSION, HANGING DROP, temperature 295K
|
Resolution 2.70 Å R-free 0.265 |
| 4RMD Crystal structure of human Retinoid X receptor alpha ligand binding domain complex with 9cUAB110 and coactivator peptide GRIP-1 Deposited 2014-10-21 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain A
228–462（235 aa）
Fragment：ligand binding domain 228-458
|
Not recorded | 3SW (2E,4E,6Z,8E)-8-[3-cyclopropyl-2-(3-methylbutyl)cyclohex-2-en-1-ylidene]-3,7-dimethylocta-2,4,6-trienoic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；295 K；5-15% PEG4000, 4-12% Glycerol, 0.1M Bis-Tris pH=7.0, VAPOR DIFFUSION, HANGING DROP, temperature 295K
|
Resolution 1.90 Å R-free 0.239 |
| 4RME Crystal structure of human Retinoid X receptor alpha ligand binding domain complex with 9cUAB111 and coactivator peptide GRIP-1 Deposited 2014-10-21 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain A
228–462（235 aa）
Fragment：ligand binding domain 228-458
|
Not recorded | 3T2 (2E,4E,6Z,8E)-3,7-dimethyl-8-[2-(3-methylbutyl)-3-(propan-2-yl)cyclohex-2-en-1-ylidene]octa-2,4,6-trienoic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；295 K；5-15% PEG4000, 4-12% Glycerol, 0.1M Bis-Tris pH=7.0, VAPOR DIFFUSION, HANGING DROP, temperature 295K
|
Resolution 2.30 Å R-free 0.273 |
| 4ZO1 Crystal Structure of the T3-bound TR-beta Ligand-binding Domain in complex with RXR-alpha Deposited 2015-05-05 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 3 PDB declaration: trimeric |
Chain B
231–455（225 aa）
Fragment：ligand binding domain, unp residues 231-455
|
Not recorded | T3 3,5,3'TRIIODOTHYRONINE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；294 K；20% PEG 3350, 100 mM Tris pH 8.0, 0.1 M ammonium acetate, and 1 mM Methoprene acid
|
Resolution 3.22 Å R-free 0.281 |
| 4ZSH RXR LBD in complex with 9-cis-13,14-dihydroretinoic acid Deposited 2015-05-13 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain A
223–462（240 aa）
Fragment：residues 223 - 462
|
Not recorded | 4XW (5S,6S,9R,13R)-2,3-didehydro-5,6,7,8,9,10,11,12,13,14-decahydroretinoic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；290 K；PEG3350 18%, calcium acetate 50 mM
|
Resolution 1.80 Å R-free 0.218 |
| 5EC9 Retinoic acid receptor alpha in complex with chiral dihydrobenzofuran benzoic acid 9a and a fragment of the coactivator TIF2 Deposited 2015-10-20 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain A
229–456（228 aa）
|
Not recorded | 5LO 4-[(11S,15R)-4,4,7,7-Tetramethyl-16-oxatetracyclo[8.6.0.03,8.011,15]hexadeca-1(10),2,8-trien-11-yl]benzoic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；277.15 K；20% w/v PEG200 MME, 0.1M Tris pH8.0, 0.2M magnesium chloride
|
Resolution 2.30 Å R-free 0.214 |
| 5JI0 PPARgamma-RXRalpha(S427F) heterodimer in complex with SRC-1, rosiglitazone, and 9-cis-retanoic acid Deposited 2016-04-21 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain A
223–462（240 aa）
|
Mutation：S427F | 9CR (9cis)-retinoic acid × 1 BRL 2,4-THIAZOLIDIINEDIONE, 5-[[4-[2-(METHYL-2-PYRIDINYLAMINO)ETHOXY]PHENYL]METHYL]-(9CL) × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；296 K；Crystals grew in the dark at room temperature from 0.5 + 0.5 uL sitting drops equilibrated over a reservoir containing 20-24% PEG3350 and 0.02M Na Citrate
|
Resolution 1.98 Å R-free 0.246 |
| 5JI0 PPARgamma-RXRalpha(S427F) heterodimer in complex with SRC-1, rosiglitazone, and 9-cis-retanoic acid Deposited 2016-04-21 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
223–462（240 aa）
|
Mutation：S427F | 9CR (9cis)-retinoic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；296 K；Crystals grew in the dark at room temperature from 0.5 + 0.5 uL sitting drops equilibrated over a reservoir containing 20-24% PEG3350 and 0.02M Na Citrate
|
Resolution 1.98 Å R-free 0.246 |
| 5LYQ Crystal structure of the Retinoic Acid Receptor alpha in complex with a synthetic spiroketal agonist and a fragment of the TIF2 co-activator. Deposited 2016-09-28 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain A
223–462（240 aa）
Fragment：UNP residues 223-462
|
Not recorded | 7BE (2~{R})-6,6,9,9-tetramethylspiro[3,4,7,8-tetrahydrobenzo[g]chromene-2,2'-3,4-dihydrochromene]-6'-carboxylic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；277 K；0.1 M MIB buffer pH 8, 25% (w/v) PEG 1500
|
Resolution 2.17 Å R-free 0.253 |
| 5MJ5 Crystal structure of the Retinoid X Receptor alpha in complex with synthetichonokiol derivative 3 and a fragment of the TIF2 co-activator. Deposited 2016-11-30 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain A
229–457（229 aa）
|
Not recorded | 7O0 (~{E})-3-[4-oxidanyl-3-[3-(phenylmethyl)phenyl]phenyl]prop-2-enoic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；277 K；0.1 M PIPES, pH 7.0, 0.1 M NaCl, 22% PEG 2K MME
|
Resolution 1.90 Å R-free 0.243 |
| 5MK4 Crystal structure of the Retinoid X Receptor alpha in complex with synthetic honokiol derivative 7 and a fragment of the TIF2 co-activator. Deposited 2016-12-02 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain A
229–457（229 aa）
Fragment：UNP residues 229-457
Chain C
229–457（229 aa）
Fragment：UNP residues 229-457
|
Not recorded | I5W (~{E})-3-[3-(2-methyl-5-phenyl-phenyl)-4-oxidanyl-phenyl]prop-2-enoic acid × 2 CL CHLORIDE ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；277 K；0.1M PIPES, pH 7.0, 0.1M NaCl, 22% PEG 2K MME
|
Resolution 2.00 Å R-free 0.229 |
| 5MKJ Crystal structure of the Retinoid X Receptor alpha in complex with synthetic honokiol derivative 9 and a fragment of the TIF2 co-activator. Deposited 2016-12-05 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain A
229–458（230 aa）
|
Not recorded | 4CU (~{E})-3-[4-oxidanyl-3-(5-prop-2-enyl-2-propoxy-phenyl)phenyl]prop-2-enoic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；277 K；0.1M PIPES, pH 7.0, 0.1M NaCl, 22% PEG 2K MME
|
Resolution 2.50 Å R-free 0.245 |
| 5MKU Crystal structure of the Retinoid X Receptor alpha in complex with synthetic honokiol derivative 4 and a fragment of the TIF2 co-activator. Deposited 2016-12-05 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain A
229–456（228 aa）
|
Not recorded | J57 (~{E})-3-[4-oxidanyl-3-(3-propan-2-ylphenyl)phenyl]prop-2-enoic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；277 K；0.1M PIPES, pH 7.0, 0.1M NaCl, 22% PEG 2K MME
|
Resolution 1.78 Å R-free 0.177 |
| 5MMW Crystal structure of the Retinoid X Receptor alpha in complex with synthetic honokiol derivative 6 and a fragment of the TIF2 co-activator. Deposited 2016-12-12 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain A
229–457（229 aa）
|
Not recorded | SJZ (~{E})-3-[3-(2-methyl-3-phenyl-phenyl)-4-oxidanyl-phenyl]prop-2-enoic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；277 K；pH 7.0, 0.1M PIPES, 0.1M NaCl, 22% PEG 2K MME
|
Resolution 2.70 Å R-free 0.253 |
| 5TBP Crystal Structure of RXR-alpha ligand binding domain complexed with synthetic modulator K8003 Deposited 2016-09-12 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
223–462（240 aa）
Fragment：UNP residues 223-462
Chain B
223–462（240 aa）
Fragment：UNP residues 223-462
Chain C
223–462（240 aa）
Fragment：UNP residues 223-462
Chain D
223–462（240 aa）
Fragment：UNP residues 223-462
|
Not recorded | 7A4 [(1Z)-5-fluoro-2-methyl-1-{[4-(propan-2-yl)phenyl]methylidene}-1H-inden-3-yl]acetic acid × 6 ACT ACETATE ION × 7 DMS DIMETHYL SULFOXIDE × 1 GOL GLYCEROL × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.6；293.15 K；0.2 ul of 0.35 mM protein and 0.6 mM ligand in 100 mM NaCl, 20 mM Tris-Cl were mixed with 0.2 ul of the well solution (20% PEG3330 and 0.2M Na Acetate)
|
Resolution 2.60 Å R-free 0.242 |
| 5TBP Crystal Structure of RXR-alpha ligand binding domain complexed with synthetic modulator K8003 Deposited 2016-09-12 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
223–462（240 aa）
Fragment：UNP residues 223-462
Chain C
223–462（240 aa）
Fragment：UNP residues 223-462
|
Not recorded | 7A4 [(1Z)-5-fluoro-2-methyl-1-{[4-(propan-2-yl)phenyl]methylidene}-1H-inden-3-yl]acetic acid × 3 ACT ACETATE ION × 4 DMS DIMETHYL SULFOXIDE × 1 GOL GLYCEROL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.6；293.15 K；0.2 ul of 0.35 mM protein and 0.6 mM ligand in 100 mM NaCl, 20 mM Tris-Cl were mixed with 0.2 ul of the well solution (20% PEG3330 and 0.2M Na Acetate)
|
Resolution 2.60 Å R-free 0.242 |
| 5TBP Crystal Structure of RXR-alpha ligand binding domain complexed with synthetic modulator K8003 Deposited 2016-09-12 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 3 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain B
223–462（240 aa）
Fragment：UNP residues 223-462
Chain D
223–462（240 aa）
Fragment：UNP residues 223-462
|
Not recorded | 7A4 [(1Z)-5-fluoro-2-methyl-1-{[4-(propan-2-yl)phenyl]methylidene}-1H-inden-3-yl]acetic acid × 3 ACT ACETATE ION × 3 GOL GLYCEROL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.6；293.15 K；0.2 ul of 0.35 mM protein and 0.6 mM ligand in 100 mM NaCl, 20 mM Tris-Cl were mixed with 0.2 ul of the well solution (20% PEG3330 and 0.2M Na Acetate)
|
Resolution 2.60 Å R-free 0.242 |
| 5UAN Crystal structure of multi-domain RAR-beta-RXR-alpha heterodimer on DNA Deposited 2016-12-19 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein–DNA Heteromer；Protein × 4 PDB declaration: hexameric |
Chain A
98–462（365 aa）
Fragment：UNP residues 98-462
|
Not recorded | ZN ZINC ION × 4 9CR (9cis)-retinoic acid × 1 REA RETINOIC ACID × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；277 K；MES, PEG300
|
Resolution 3.51 Å R-free 0.270 |
| 5Z12 A structure of FXR/RXR Deposited 2017-12-23 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain B
228–458（231 aa）
Fragment：UNP residues 228-458
|
Not recorded | 33Y 1-methylethyl 3-[(3,4-difluorophenyl)carbonyl]-1,1-dimethyl-1,2,3,6-tetrahydroazepino[4,5-b]indole-5-carboxylate × 1 9CR (9cis)-retinoic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；4% v/v Tacsimate pH 8.0, 12% w/v Polyethylene glycol 3,350
|
Resolution 2.75 Å R-free 0.290 |
| 5Z12 A structure of FXR/RXR Deposited 2017-12-23 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain C
228–458（231 aa）
Fragment：UNP residues 228-458
|
Not recorded | 33Y 1-methylethyl 3-[(3,4-difluorophenyl)carbonyl]-1,1-dimethyl-1,2,3,6-tetrahydroazepino[4,5-b]indole-5-carboxylate × 1 9CR (9cis)-retinoic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；4% v/v Tacsimate pH 8.0, 12% w/v Polyethylene glycol 3,350
|
Resolution 2.75 Å R-free 0.290 |
| 5ZQU Crystal structure of tetrameric RXRalpha-LBD complexed with partial agonist CBt-PMN Deposited 2018-04-20 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
224–462（239 aa）
Chain B
224–462（239 aa）
Chain C
224–462（239 aa）
Chain D
224–462（239 aa）
|
Not recorded | 9HF 1-(3,5,5,8,8-pentamethyl-6,7-dihydronaphthalen-2-yl)benzotriazole-5-carboxylic acid × 6 BR BROMIDE ION × 11 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；293 K；200mM sodium bromide, 20% polyethylene glycol 3350
|
Resolution 2.60 Å R-free 0.270 |
| 6A5Y Crystal structure of human FXR/RXR-LBD heterodimer bound to HNC143 and 9cRA and SRC1 Deposited 2018-06-25 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain D
225–462（238 aa）
|
Not recorded | 9R0 2-[2-[[3-[2,6-bis(chloranyl)phenyl]-5-cyclopropyl-1,2-oxazol-4-yl]methoxy]-6-azaspiro[3.4]octan-6-yl]-1,3-benzothiazole-6-carboxylic acid × 1 SO4 SULFATE ION × 2 9CR (9cis)-retinoic acid × 1 PO4 PHOSPHATE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 5.6；293 K；0.2M Ammonium sulfate , 0.1M tri-sodium citrate,25%PEG 4000
|
Resolution 2.10 Å R-free 0.241 |
| 6A5Z Crystal structure of human FXR/RXR-LBD heterodimer bound to HNC180 and 9cRA and SRC1 Deposited 2018-06-25 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain D
225–462（238 aa）
Fragment：ligand binding domain
|
Not recorded | 9R3 2-[(1R,5S)-9-[[3-[2,6-bis(chloranyl)phenyl]-5-cyclopropyl-1,2-oxazol-4-yl]methoxy]-3-azabicyclo[3.3.1]nonan-3-yl]-1,3-benzothiazole-6-carboxylic acid × 1 9CR (9cis)-retinoic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；277 K；0.2 M Ammonium iodide, 20% w/v Polyethylene glycol 3,350
|
Resolution 2.95 Å R-free 0.282 |
| 6A5Z Crystal structure of human FXR/RXR-LBD heterodimer bound to HNC180 and 9cRA and SRC1 Deposited 2018-06-25 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain L
225–462（238 aa）
Fragment：ligand binding domain
|
Not recorded | 9R3 2-[(1R,5S)-9-[[3-[2,6-bis(chloranyl)phenyl]-5-cyclopropyl-1,2-oxazol-4-yl]methoxy]-3-azabicyclo[3.3.1]nonan-3-yl]-1,3-benzothiazole-6-carboxylic acid × 1 9CR (9cis)-retinoic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；277 K；0.2 M Ammonium iodide, 20% w/v Polyethylene glycol 3,350
|
Resolution 2.95 Å R-free 0.282 |
| 6A60 Crystal structure of human FXR/RXR-LBD heterodimer bound to GW4064 and 9cRA and SRC1 Deposited 2018-06-25 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain D
225–462（238 aa）
|
Not recorded | 064 3-[(E)-2-(2-chloro-4-{[3-(2,6-dichlorophenyl)-5-(1-methylethyl)isoxazol-4-yl]methoxy}phenyl)ethenyl]benzoic acid × 1 9CR (9cis)-retinoic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 7；277 K；0.1 M Sodium acetate trihydrate, 12% PEG3350
|
Resolution 3.05 Å R-free 0.288 |
| 6FBQ Crystal Structure of the Human Retinoid X Receptor DNA-Binding Domain Bound to the Human MEp DR1 Response Element, pH 7.0 Deposited 2017-12-19 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein–DNA Homooligomer；Protein × 2 PDB declaration: tetrameric |
Chain A
33–115（83 aa）
Chain B
33–115（83 aa）
|
Not recorded | ZN ZINC ION × 4 MPO 3[N-MORPHOLINO]PROPANE SULFONIC ACID × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7；293 K；20% PEG 3350, 0.1M MOPS pH 7.0, 0.1M NH4Cl, 0.1M MgCl2
|
Resolution 1.60 Å R-free 0.198 |
| 6FBR Crystal Structure of the Human Retinoid X Receptor DNA-Binding Domain Bound to the Human MEp DR1 Response Element, pH 4.2 Deposited 2017-12-19 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein–DNA Homooligomer；Protein × 2 PDB declaration: tetrameric |
Chain A
33–115（83 aa）
Chain B
33–115（83 aa）
|
Not recorded | ZN ZINC ION × 2 PO4 PHOSPHATE ION × 1 PGE TRIETHYLENE GLYCOL × 1 PEG DI(HYDROXYETHYL)ETHER × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4.2；293 K；40% PEG 300, 0.1M sodium phosphate citrate pH 4.2
|
Resolution 2.10 Å R-free 0.232 |
| 6HN6 A revisited version of the apo structure of the ligand-binding domain of the human nuclear receptor RXR-ALPHA Deposited 2018-09-14 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
201–462（262 aa）
|
Not recorded | CPS 3-[(3-CHOLAMIDOPROPYL)DIMETHYLAMMONIO]-1-PROPANESULFONATE × 8 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；289 K；0.45 M AMMONIUM CITRATE, 30 mM KCl, 4% GLYCEROL, 5 mM CHAPS, pH 7.0
|
Resolution 2.71 Å R-free 0.231 |
| 6JNO RXRa structure complexed with CU-6PMN Deposited 2019-03-17 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
224–462（239 aa）
Chain B
224–462（239 aa）
Chain C
224–462（239 aa）
Chain D
224–462（239 aa）
|
Not recorded | WY5 7-oxidanyl-2-oxidanylidene-6-(3,5,5,8,8-pentamethyl-6,7-dihydronaphthalen-2-yl)chromene-3-carboxylic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8；295 K；20% (w/v) Polyethylene glycol 3350, 0.2M Mg(OAc)2
|
Resolution 2.65 Å R-free 0.274 |
| 6JNR RXRa structure complexed with CU-6PMN and SRC1 peptide. Deposited 2019-03-18 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain A
224–462（239 aa）
Chain B
224–462（239 aa）
|
Not recorded | WY5 7-oxidanyl-2-oxidanylidene-6-(3,5,5,8,8-pentamethyl-6,7-dihydronaphthalen-2-yl)chromene-3-carboxylic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；295 K；30%(v/v) Polyethylene glycol monomethyl ether 550, 0.1M HEPES-NaOH (pH 7.5), 0.05M MgCl2
|
Resolution 2.30 Å R-free 0.238 |
| 6L6K Crystal structure of dimeric RXRalpha-LBD complexed with partial agonist CBt-PMN and SRC1 Deposited 2019-10-29 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain A
224–462（239 aa）
|
Not recorded | 9HF 1-(3,5,5,8,8-pentamethyl-6,7-dihydronaphthalen-2-yl)benzotriazole-5-carboxylic acid × 2 CA CALCIUM ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；20mM Calcium acetate hydrate, 20% Polyethylene glycol 3.350, 10mM Praseodymium(III) acetate hydrate
|
Resolution 1.80 Å R-free 0.211 |
| 6LB4 Crystal structure of dimeric RXR-LBD complexed with NEt-3ME and TIF2 co-activator Deposited 2019-11-13 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain A
224–462（239 aa）
|
Not recorded | E8L 6-[ethyl-[3-(2-methoxyethoxy)-4-propan-2-yl-phenyl]amino]pyridine-3-carboxylic acid × 2 EDO 1,2-ETHANEDIOL × 8 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；0.2 M Sodium Acetate
18 % PEG3350
0.1 M Spermine tetrahydrochroride
|
Resolution 1.50 Å R-free 0.201 |
| 6LB5 Crystal structure of dimeric RXR-LBD complexed with full agonist NEt-3IB and TIF2 co-activator Deposited 2019-11-13 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain A
224–462（239 aa）
Chain C
224–462（239 aa）
|
Not recorded | E80 6-[ethyl-[3-(2-methylpropoxy)-4-propan-2-yl-phenyl]amino]pyridine-3-carboxylic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7；293 K；0.1 M Imidazole
20 % PEG 6000
|
Resolution 2.40 Å R-free 0.240 |
| 6LB6 Crystal structure of dimeric RXR-LBD complexed with partial agonist NEt-4IB and TIF2 co-activator Deposited 2019-11-13 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain A
224–462（239 aa）
|
Not recorded | E8O 6-[ethyl-[4-(2-methylpropoxy)-3-propan-2-yl-phenyl]amino]pyridine-3-carboxylic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7；293 K；0.1 M Imidazole
20 % PEG6000
|
Resolution 2.40 Å R-free 0.257 |
| 6SJM Crystal structure of the Retinoic Acid Receptor alpha in complex with compound 24 (JP175) Deposited 2019-08-13 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain A
229–456（228 aa）
|
Not recorded | LFZ 2-[4-[3,5-bis(trifluoromethyl)phenyl]phenyl]ethanoic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；293.15 K；21% PEG 4000, 0.2 M ammonium acetate and 0.1 M tris, pH 7.5
|
Resolution 2.52 Å R-free 0.247 |
| 6STI Crystal structure of RXRalpha LBD in complex with LG 100754 and a coactivator peptide Deposited 2019-09-10 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain A
223–462（240 aa）
|
Not recorded | 754 (2E,4E,6Z)-3-methyl-7-(5,5,8,8-tetramethyl-3-propoxy-5,6,7,8-tetrahydronaphthalen-2-yl)octa-2,4,6-trienoic acid × 2 ACT ACETATE ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；17.5% PEG3350, 0.7 M CH3COONH4, 30 mM CH3COONa pH4.6
|
Resolution 1.89 Å R-free 0.172 |
| 6XWG Crystal Structure of the Human RXR/RAR DNA-Binding Domain Heterodimer Bound to the Human RARb2 DR5 Response Element Deposited 2020-01-23 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein–DNA Heteromer；Protein × 2 PDB declaration: tetrameric |
Chain C
33–115（83 aa）
|
Not recorded | ZN ZINC ION × 4 GOL GLYCEROL × 1 CL CHLORIDE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；293 K；25% PEG 3350, 0.2 M Li2SO4, 0.1 M bis-tris pH 6.5
|
Resolution 2.40 Å R-free 0.207 |
| 6XWH Crystal Structure of the Human RXR DNA-Binding Domain Homodimer Bound to the Human Hoxb13 DR0 Response Element Deposited 2020-01-23 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein–DNA Homooligomer；Protein × 2 PDB declaration: tetrameric |
Chain C
33–115（83 aa）
Chain D
33–115（83 aa）
|
Not recorded | ZN ZINC ION × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；20% PEG 3350, 0.15 M di-sodium DL-malonate
|
Resolution 2.10 Å R-free 0.224 |
| 7A77 Crystal structure of RXR alpha LBD in complexes with palmitic acid and GRIP-1 peptide Deposited 2020-08-27 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain A
223–462（240 aa）
|
Not recorded | EDO 1,2-ETHANEDIOL × 8 PLM PALMITIC ACID × 2 CL CHLORIDE ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8；293.15 K；17% PEG 3350, 0.2M ammonium actetate, 0.1M tris, pH 8.0
|
Resolution 1.50 Å R-free 0.180 |
| 7B88 Crystal structure of Retinoic Acid Receptor alpha (RXRA) in complexed with S99 inhibitor Deposited 2020-12-12 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain A
229–456（228 aa）
|
Not recorded | T2K 3-[5-[3,5-bis(chloranyl)phenyl]-4-phenyl-1,3-oxazol-2-yl]propanoic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；293.15 K；21% PEG 3350, 0.1 M Ammomium Acetate, 0.1 M tris 7.5
|
Resolution 2.38 Å R-free 0.259 |
| 7B9O Crystal structure of Retinoic Acid Receptor alpha (RXRA) in complexed with S169 inhibitor Deposited 2020-12-14 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain A
229–456（228 aa）
|
Not recorded | T72 3-(5-(3,5-bis(trifluoromethyl)phenyl)-4-phenyloxazol-2-yl)propanoic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；24% PEG 4000
0.2M Ammonium acetate
0.1M Tris pH7.5
|
Resolution 2.05 Å R-free 0.236 |
| 7BK4 Crystal structure of RXRalpha ligand binding domain in complex with a fragment of the TIF2 coactivator Deposited 2021-01-15 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain A
223–462（240 aa）
Chain C
223–462（240 aa）
|
Not recorded | LG2 6-[1-(3,5,5,8,8-PENTAMETHYL-5,6,7,8-TETRAHYDRONAPHTHALEN-2-YL)CYCLOPROPYL]PYRIDINE-3-CARBOXYLIC ACID × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；0.1 M Na Hepes, 0.2 M sodium acetate pH 7.5, 27% PEG 3350
|
Resolution 2.80 Å R-free 0.265 |
| 7CFO Crystal structure of human RXRalpha ligand binding domain complexed with CBTF-EE. Deposited 2020-06-27 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
224–462（239 aa）
Fragment：ligand binding domain
Chain B
224–462（239 aa）
Fragment：ligand binding domain
Chain C
224–462（239 aa）
Fragment：ligand binding domain
Chain D
224–462（239 aa）
Fragment：ligand binding domain
|
Not recorded | WZ6 1-[3-(2-ethoxyethoxy)-5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl]-2-(trifluoromethyl)benzimidazole-5-carboxylic acid × 3 GOL GLYCEROL × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7；295 K；5% [v/v] tacsimateTM [pH 7.0], 0.1 M HEPES [pH 7.0], and 10% [w/v] PEGMME5000
|
Resolution 2.15 Å R-free 0.266 |
| 7NKE Crystal structure of human RXRalpha ligand binding domain in complex with 2,4-di-tert-butylphenol and a coactivator fragment Deposited 2021-02-17 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain A
223–462（240 aa）
Chain C
223–462（240 aa）
|
Not recorded | UGW 2,4-di~{tert}-butylphenol × 2 FMT FORMIC ACID × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；293 K；20% PEG 3350
0.2 M sodium formate
|
Resolution 2.35 Å R-free 0.246 |
| 7UW2 Crystal structure of human Retinoid X receptor alpha ligand binding domain complex with UAB116 and coactivator peptide GRIP-1 Deposited 2022-05-02 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
223–462（240 aa）
|
Not recorded | OI2 (2E,4E,6Z,8E)-8-{3-[(2S)-butan-2-yl]-2-(3-methylbutyl)cyclohex-2-en-1-ylidene}-3,7-dimethylocta-2,4,6-trienoic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；295 K；100 mM Bis-Tris, pH 7.0, 8% PEG4000, 25% ethylene glycol. The drop contained 2 ul protein + 1 ul well solution
|
Resolution 1.88 Å R-free 0.218 |
| 7UW4 Crystal structure of human Retinoid X receptor alpha ligand binding domain complex with UAB113 and coactivator peptide GRIP-1 Deposited 2022-05-02 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
223–462（240 aa）
|
Not recorded | OI5 (2E,4E,6Z,8E)-3,7-dimethyl-8-[2-(3-methylbutyl)-3-propylcyclohex-2-en-1-ylidene]octa-2,4,6-trienoic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；295 K；100 mM Bis-Tris, pH 7.0, 7% PEG4000, 5% ethylene glycol
|
Resolution 2.10 Å R-free 0.243 |
| 8HBM Structural basis of the farnesoid X receptor/retinoid X receptor heterodimer on inverted repeat DNA Deposited 2022-10-29 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein–DNA Heteromer；Protein × 2 PDB declaration: tetrameric |
Chain A
130–212（83 aa）
|
Not recorded | ZN ZINC ION × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；291 K；100mM BTP pH 6.7, 10mM MgCl2, 50mM MgSO4, 50mM Li2SO4, 5mM DTT, 16% PEG 3350
|
Resolution 3.30 Å R-free 0.301 |
| 8HBM Structural basis of the farnesoid X receptor/retinoid X receptor heterodimer on inverted repeat DNA Deposited 2022-10-29 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein–DNA Heteromer；Protein × 2 PDB declaration: tetrameric |
Chain E
130–212（83 aa）
|
Not recorded | ZN ZINC ION × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；291 K；100mM BTP pH 6.7, 10mM MgCl2, 50mM MgSO4, 50mM Li2SO4, 5mM DTT, 16% PEG 3350
|
Resolution 3.30 Å R-free 0.301 |
| 8PP0 Crystal structure of Retinoic Acid Receptor alpha (RXRA) in complexed with JP147 Deposited 2023-07-05 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
223–462（240 aa）
|
Not recorded | 7QJ 3-[4-[2,3-dihydro-1H-inden-4-yl(methyl)amino]-6-(trifluoromethyl)pyrimidin-2-yl]oxypropanoic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293.15 K；23% PEG 3350, 0.1 M Ammonium actetate, 0.1 M tris pH 7.5
|
Resolution 1.90 Å R-free 0.223 |
| 9QJ9 Crystal Structure of the Human Retinoid X Receptor DNA-Binding Domain Bound to Trim16 IR1 Response Element Deposited 2025-03-18 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein–DNA Homooligomer；Protein × 2 PDB declaration: tetrameric |
Chain A
33–115（83 aa）
Chain B
33–115（83 aa）
|
Not recorded | ZN ZINC ION × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；290 K；20% PEG 1000, 0.2M MgCl2 0.1M NaCl, 0.05M Na cacodylate pH6.5
|
Resolution 3.50 Å R-free 0.335 |
| 9QX6 Crystal structure of RXR alpha LBD bound to a synthetic agonist FN537 and a coactivator fragment Deposited 2025-04-15 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
229–462（234 aa）
|
Not recorded | A1JAT (6R,6aR,7S,10R,10aS)-6-(3,5-bis(trifluoromethyl)phenyl)-5,6,6a,7,8,9,10,10a-octahydro-7,10-methanophenanthridine-3-carboxylic acid × 1 A1JHO 6S,6aS,7R,10S,10aR)-6-(3,5-bis(trifluoromethyl)phenyl)-5,6,6a,7,8,9,10,10a-octahydro-7,10-methanophenanthridine-3-carboxylic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；289 K；20% PEG3350, 0.2M calcium acetate
|
Resolution 1.46 Å R-free 0.213 |
| 9RMR Crystal structure of RXR alpha LBD bound to a synthetic agonist FN558 and a coactivator fragment Deposited 2025-06-18 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
229–462（234 aa）
|
Not recorded | A1JH6 FN558 × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；277 K；20% PEG 3350, 0.1 M magnesium actetate
|
Resolution 1.65 Å R-free 0.215 |
| 9S70 Crystal structure of RXR alpha LBD bound to a partial agonist 21 and a coactivator fragment SRC1 Deposited 2025-08-01 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
229–462（234 aa）
|
Not recorded | A1JL7 3-[[4-cyclobutyl-6-(3,4-dihydro-2~{H}-quinolin-1-yl)pyrimidin-2-yl]amino]propanoic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；277 K；20% PEG2000, 0.1M Mes pH 6.5
|
Resolution 1.95 Å R-free 0.221 |
| 9S71 Crystal structure of RXR alpha LBD bound to a partial agonist 35 and a coactivator fragment SRC1 Deposited 2025-08-01 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
229–462（234 aa）
|
Not recorded | A1JL8 3-[[4-(4,4-dimethyl-2,3-dihydroquinolin-1-yl)-6-(trifluoromethyl)pyrimidin-2-yl]amino]propanoic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；277 K；18% PEG 4000 0.1 M MES pH 6.5
|
Resolution 2.00 Å R-free 0.222 |
107 other PDB entries and 138 assemblies. Open the comparison page and filter oligomeric states
View Construct and Data Evidence
| UniProt name | RXRA_HUMAN |
| Isoform | — |
| PDB entities | 1 |
| Chains and sequence ranges | Author chain A； PDBConstruct 1–83； UniProt 130–212 |
